Yi Zhang

11PUBLICATIONS
24CO-AUTHORS
Molecular targetsNanotoxicology, health and safetyHaematological tumoursMolecular medicineMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 29, 2026
Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

|Jul 05, 2024
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.

Shanshan Suo, Dandan Zhao, Fenglin Li

|Feb 28, 2024
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis.

Rong Wang, Yi Zhang, Jie Chang

|Feb 12, 2024
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.

Yi Zhang, Hu Zhou, Zhongxing Jiang

|Jul 20, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.

Yi Zhang, Hu Zhou, Minghui Duan

|Jul 19, 2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.

Yi Zhang, Qike Zhang, Qingchi Liu

Pageof 2

Frequent Collaborators

10 joint publications

Jie Jin

3 joint publications

Huafeng Wang

3 joint publications

Hongyan Tong

3 joint publications

Hong-Hu Zhu